Get started
Author

Julio C. C. Lorenzi

Observed names: J C C Lorenzi, J. C. C. Lorenzi, J. Lorenzi, J.C. Cetrulo Lorenzi, J.C. Lorenzi, J.C.C. Lorenzi, Julio C C Lorenzi, Julio C Cetrulo Lorenzi, Julio C. Cesar Lorenzi, Julio C. Cetrulo Lorenzi, Julio C.C. Lorenzi, Julio CC Lorenzi, Julio Cesar Cetrulo Lorenzi, Julio Lorenzi, Júlio CC Lorenzi, Júlio Cesar Cetrulo Lorenzi, Júlio César C. Lorenzi, Júlio César Cetrulo Lorenzi, Lorenzi, Julio, Lorenzi, Julio Cesar Cetrulo
Observed institutions: Conselho Nacional de Desenvolvimento Científico e Tecnológico, Howard Hughes Medical Institute, Universidade de São Paulo, Universidade Federal de Alfenas, Karolinska Institutet, Fundação de Amparo à Pesquisa do Estado de São Paulo, Rockefeller University
ORCID: 0000-0003-2492-3961
Observed ORCID: 0000-0003-2492-3961
OpenAlex ID: A5086462012
Convergent antibody responses to SARS-CoV-2 in convalescent individuals
2020 · Davide F. Robbiani, Christian Gaebler, et al. · Nature · 1,850
PDF
Evolution of antibody immunity to SARS-CoV-2
2021 · Christian Gaebler, Zijun Wang, et al. · Nature · 1,665
PDF
Structures of Human Antibodies Bound to SARS-CoV-2 Spike Reveal Common Epitopes and Recurrent Features of Antibodies
2020 · Christopher O. Barnes, Anthony P. West, et al. · Cell · 792
Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117
2015 · Marina Caskey, Florian Klein, et al. · Nature · 766
Measuring SARS-CoV-2 neutralizing antibody activity using pseudotyped and chimeric viruses
2020 · Fabian Schmidt, Yiska Weisblum, et al. · The Journal of Experimental Medicine · 571
Combination therapy with anti-HIV-1 antibodies maintains viral suppression
2018 · Pilar Mendoza, Henning Gruell, et al. · Nature · 521
Enhanced SARS-CoV-2 neutralization by dimeric IgA
2020 · Zijun Wang, Julio C. C. Lorenzi, et al. · Science Translational Medicine · 474
PDF
HIV-1 antibody 3BNC117 suppresses viral rebound in humans during treatment interruption
2016 · Johannes F. Scheid, Joshua A. Horwitz, et al. · Nature · 472
Passive transfer of modest titers of potent and broadly neutralizing anti-HIV monoclonal antibodies block SHIV infection in macaques
2014 · Masashi Shingai, Olivia K. Donau, et al. · The Journal of Experimental Medicine · 321
HIV-1 therapy with monoclonal antibody 3BNC117 elicits host immune responses against HIV-1
2016 · Till Schoofs, Florian Klein, et al. · Science · 312
Longitudinal Serological Analysis and Neutralizing Antibody Levels in Coronavirus Disease 2019 Convalescent Patients
2020 · Frauke Muecksch, Helen Wise, et al. · The Journal of Infectious Diseases · 307
PDF
Antibody potency, effector function, and combinations in protection and therapy for SARS-CoV-2 infection in vivo
2020 · Alexandra Schäfer, Frauke Muecksch, et al. · The Journal of Experimental Medicine · 304
Affinity maturation of SARS-CoV-2 neutralizing antibodies confers potency, breadth, and resilience to viral escape mutations
2021 · Frauke Muecksch, Yiska Weisblum, et al. · Immunity · 277
PDF
Nanobodies from camelid mice and llamas neutralize SARS-CoV-2 variants
2021 · Jianliang Xu, Kai Xu, et al. · Nature · 233
PDF
Paired quantitative and qualitative assessment of the replication-competent HIV-1 reservoir and comparison with integrated proviral DNA
2016 · Julio C. C. Lorenzi, Yehuda Z. Cohen, et al. · Proceedings of the National Academy of Sciences · 174
PDF
Coexistence of potent HIV-1 broadly neutralizing antibodies and antibody-sensitive viruses in a viremic controller
2017 · Natalia T. Freund, Haoqing Wang, et al. · Science Translational Medicine · 169
Non-neutralizing Antibodies Alter the Course of HIV-1 Infection In Vivo
2017 · Joshua A. Horwitz, Yotam Bar-On, et al. · Cell · 152
PDF
Bispecific IgG neutralizes SARS-CoV-2 variants and prevents escape in mice
2021 · Raoul De Gasparo, Mattia Pedotti, et al. · Nature · 137
PDF
Clonal CD4+ T cells in the HIV-1 latent reservoir display a distinct gene profile upon reactivation
2018 · Lillian B. Cohn, Israel T. da Silva, et al. · Nature Medicine · 136
Relationship between latent and rebound viruses in a clinical trial of anti–HIV-1 antibody 3BNC117
2018 · Yehuda Z. Cohen, Julio C.C. Lorenzi, et al. · The Journal of Experimental Medicine · 117
Combination of quadruplex qPCR and next-generation sequencing for qualitative and quantitative analysis of the HIV-1 latent reservoir
2019 · Christian Gaebler, Julio C.C. Lorenzi, et al. · The Journal of Experimental Medicine · 116
Autologous hematopoietic SCT normalizes miR-16, -155 and -142-3p expression in multiple sclerosis patients
2014 · L C M Arruda, J C C Lorenzi, et al. · Bone Marrow Transplantation · 103
Safety, pharmacokinetics, and immunogenicity of the combination of the broadly neutralizing anti-HIV-1 antibodies 3BNC117 and 10-1074 in healthy adults: A randomized, phase 1 study
2019 · Yehuda Z. Cohen, Allison L. Butler, et al. · PLoS ONE · 90
PDF
Heightened resistance to host type 1 interferons characterizes HIV-1 at transmission and after antiretroviral therapy interruption
2021 · Marcos V. P. Gondim, Scott Sherrill-Mix, et al. · Science Translational Medicine · 84
PDF
Longitudinal clonal dynamics of HIV-1 latent reservoirs measured by combination quadruplex polymerase chain reaction and sequencing
2022 · Alice Cho, Christian Gaebler, et al. · Proceedings of the National Academy of Sciences · 83
Works count: 77
Citation count: 11,270
H-index: 37
I10-index: 54
Year
Topic
Type